title: Waldenström's macroglobulinaemia: laboratory diagnosis and treatment.
authors.affiliation: Department of Haematology, The General Infirmary at Leeds, UK. rgo@ukgateway.net
authors.forename: R G
authors.initials: RG
authors.lastname: Owen
authors.forename: S A
authors.initials: SA
authors.lastname: Johnson
authors.forename: G J
authors.initials: GJ
authors.lastname: Morgan
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000782:Aneuploidy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology; D001809:Blood Viscosity; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002869:Chromosome Aberrations; D003449:Cryoglobulinemia / Q000209:etiology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D016130:Immunophenotyping; D015994:Incidence; D008223:Lymphoma / Q000145:classification / Q000150:complications; D008297:Male; D008875:Middle Aged; D010266:Paraproteins / Q000032:analysis; D010956:Plasmapheresis; D011379:Prognosis; D000069283:Rituximab; D016879:Salvage Therapy; D008258:Waldenstrom Macroglobulinemia / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D010266:Paraproteins; D000074323:Alemtuzumab; D000069283:Rituximab